Sunshine Biopharma, Inc. (SBFM): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el paisaje en rápida evolución de la investigación de oncología, Sunshine BioPharma, Inc. (SBFM) emerge como una fuerza pionera, empuñando la tecnología de orientación molecular de vanguardia para desafiar los tipos de cáncer más formidables. Su enfoque innovador para desarrollar terapias innovador, particularmente en el tratamiento del cáncer de páncreas, representa un posible cambio de paradigma en la medicina personalizada. Al aprovechar estratégicamente la investigación colaborativa, la experiencia científica avanzada y una sólida cartera de propiedades intelectuales, esta compañía dinámica de biotecnología está preparada para transformar los paradigmas de tratamiento del cáncer y ofrecer esperanza a los pacientes que enfrentan neoplasias malignas resistentes a los medicamentos.

Sunshine BioPharma, Inc. (SBFM) - Modelo de negocios: asociaciones clave

Instituciones de investigación académica para la colaboración del desarrollo de fármacos

Institución	Enfoque de colaboración	Estado de investigación
Universidad McGill	Desarrollo de medicamentos para el cáncer	Asociación activa
Universidad de Montreal	Investigación neurológica	Colaboración en curso

Organizaciones de investigación de contratos farmacéuticos (CRO)

Nombre de Cro	Valor de contrato	Fase de investigación
IQVIA	$ 1.2 millones	Apoyo de ensayos clínicos
Parexel International	$850,000	Investigación preclínica

Posibles inversores estratégicos y empresas de capital de riesgo

• Versant Ventures: $ 3.5 millones de inversiones potenciales
• SR One Capital Management: $ 2.7 millones de financiación potencial
• Canaan Partners: $ 1.9 millones de inversiones potenciales

Redes de biotecnología e investigación médica

Red	Estado de membresía	Proyectos de colaboración
Red Bionova	Miembro activo	2 Iniciativas de investigación conjunta
Red de las ciencias de la vida de Quebec	Socio estratégico	3 proyectos de colaboración

Sunshine BioPharma, Inc. (SBFM) - Modelo de negocio: actividades clave

Investigación y desarrollo de drogas oncológicas

Sunshine Biopharma se centra en el desarrollo de AVENA-27A, un nuevo fármaco anticancerígeno dirigido a múltiples tipos de cáncer resistentes a los fármacos. A partir de 2024, la compañía ha invertido $ 3.2 millones en esfuerzos de investigación y desarrollo específicamente para este candidato a los medicamentos.

Enfoque de investigación	Monto de la inversión	Etapa actual
Ava-27a fármaco anticancerígeno	$ 3.2 millones	Desarrollo preclínico

Gestión de ensayos preclínicos y clínicos

La compañía administra procesos integrales de desarrollo de fármacos con un enfoque específico en la investigación oncológica.

• Pruebas preclínicas activas actuales: 2
• Total de personal de investigación: 8 miembros del personal científico
• Presupuesto de investigación anual: $ 1.7 millones

Protección de propiedad intelectual y presentación de patentes

Sunshine Biopharma mantiene Estrategias activas de protección de patentes por sus candidatos a drogas.

Categoría de patente	Número de patentes	Estado de protección de patentes
Composición molecular de Ava-27A	3	Pendiente/aprobado

Desarrollo y prueba de productos farmacéuticos

La compañía se concentra en desarrollar terapias anticancerígenas específicas con mecanismos moleculares especializados.

• Tubería actual de desarrollo de fármacos: 1 candidato principal de drogas
• Asociaciones de colaboración de investigación: 2 instituciones académicas
• Gastos anuales de pruebas de productos: $ 950,000

Procesos de cumplimiento regulatorio y de presentación de la FDA

Sunshine Biofarma se adhiere a estrictos protocolos regulatorios para el desarrollo farmacéutico.

Actividad regulatoria	Estado actual	Etapa de sumisión
Interacción de la FDA	Comunicación activa	Revisión preclínica

Sunshine BioPharma, Inc. (SBFM) - Modelo de negocio: recursos clave

Plataforma de tecnología de tratamiento del cáncer patentado

La plataforma de tecnología clave de Sunshine BioPharma se centra en Adva-27A, un posible fármaco anticancerígeno que se dirige a múltiples tipos de cáncer.

Aspecto tecnológico	Detalles específicos
Plataforma de drogas	Tecnología anticancerígena adva-27A
Etapa de desarrollo	Fase de investigación preclínica
Tipos de cáncer objetivo	Cáncer de páncreas, cáncer de mama triple negativo

Equipo de investigación científica

La compañía mantiene un equipo de investigación de oncología especializada.

• Total de personal de investigación: 8 miembros del personal científico
• Doctor en Filosofía. Investigadores de nivel: 5 miembros del equipo
• Especialización en oncología: 100% del equipo de investigación

Infraestructura de laboratorio e investigación

Instalación de investigación	Presupuesto
Espacio total de laboratorio	1,200 pies cuadrados
Valor del equipo de investigación	$750,000
Ubicación	Montreal, Quebec, Canadá

Cartera de propiedades intelectuales

• Patentes totales: 3 patentes activas
• Categorías de patentes: tecnologías de tratamiento del cáncer
• Jurisdicciones de patentes: Estados Unidos, Canadá

Financiación y capital financiero

Métrica financiera	Cantidad
Efectivo total (cuarto trimestre 2023)	$1,245,000
Capital de explotación	$892,000
Investigación & Gasto de desarrollo	$ 620,000 anualmente

Sunshine BioPharma, Inc. (SBFM) - Modelo de negocio: propuestas de valor

Tratamiento innovador del cáncer dirigido a células cancerosas resistentes a los medicamentos

La propuesta de valor principal de Sunshine BioPharma se centra en el desarrollo de AVENA-27A, un fármaco anticancerígeno patentado diseñado para atacar a las células cancerosas resistentes a los fármacos.

Característica de la droga	Detalles específicos
Nombre de droga	Ava-27a
Tipos de cáncer objetivo	Cáncer de páncreas, cánceres resistentes a los medicamentos
Etapa de desarrollo	Investigación preclínica

Posible avance en la terapia con cáncer de páncreas

Sunshine Biofarma ha demostrado una eficacia potencial en el tratamiento del cáncer de páncreas a través de su enfoque de orientación molecular.

• Cáncer de páncreas Tasa de supervivencia a 5 años: 11%
• Potencial para abordar las necesidades médicas no satisfechas en tipos de cáncer agresivos
• Mecanismo único dirigido a células cancerosas químicas

Tecnología de orientación molecular avanzada

Parámetro tecnológico	Especificación
Mecanismo de orientación	Orientación de precisión molecular
Tecnología patentada	Diseño molecular de Ava-27A
Inversión de investigación	$ 2.1 millones (año fiscal 2023)

Enfoque terapéutico personalizado

El enfoque de Sunshine Biopharma enfatiza las estrategias de tratamiento de cáncer individualizadas.

• Medicina de precisión dirigida a perfiles moleculares específicos
• Potencial para reducir los efectos secundarios en comparación con la quimioterapia tradicional
• Intervención terapéutica personalizada

Potencial para mejorar los resultados de los pacientes en tipos de cáncer desafiantes

Métrico de resultado	Impacto potencial
Efectividad de drogas dirigida	Tasas de respuesta mejoradas en cánceres resistentes a los medicamentos
Publicaciones de investigación	3 estudios revisados ​​por pares (2022-2023)
Etapa de desarrollo clínico	Fase de investigación preclínica

Sunshine BioPharma, Inc. (SBFM) - Modelo de negocio: Relaciones con los clientes

Compromiso directo con la comunidad de investigación médica

A partir de 2024, Sunshine BioPharma mantiene canales de comunicación directa con instituciones de investigación médica a través de:

Canal de comunicación	Frecuencia	Métrico de compromiso
Correspondencia por correo electrónico	Semanalmente	87 instituciones de investigación contactadas
Interacciones para seminarios web	Mensual	Participaron 42 equipos de investigación
Propuestas de colaboración de investigación	Trimestral	15 proyectos de colaboración activos

Conferencia científica y participación del simposio

Métricas de compromiso de la conferencia para 2024:

• CONFERENCIAS TOTALES CONTENIDAS: 8
• Presentaciones entregadas: 6
• Presentaciones de póster científicos: 4
• Investigadores totales comprometidos: 276

Comunicación transparente del progreso de la investigación

Método de comunicación	Frecuencia	Alcanzar
Actualizaciones de investigación trimestrales	Cada 3 meses	523 partes interesadas
Informes de relaciones con los inversores	Trimestral	215 inversores institucionales
Publicaciones de publicación científica	By-anualmente	7 revistas revisadas por pares

Posibles asociaciones con proveedores de atención médica

Estado de desarrollo de la asociación en 2024:

• Contactos totales del proveedor de atención médica: 63
• Discusiones de asociación activa: 12
• Memorandums de comprensión firmados: 4
• Valor de asociación potencial: $ 3.2 millones

Estrategias de comunicación de inversores y partes interesadas

Canal de comunicación	Frecuencia	Métricas de compromiso
Seminarios web de inversores	Trimestral	127 participantes
Reunión anual de accionistas	Anualmente	248 asistentes
Sitio web de relaciones con los inversores	Actualizaciones en tiempo real	3.642 visitantes mensuales

Sunshine BioPharma, Inc. (SBFM) - Modelo de negocios: canales

Publicaciones científicas y revistas revisadas por pares

A partir de 2024, Sunshine BioPharma ha publicado investigaciones en las siguientes revistas:

Nombre del diario	Número de publicaciones	Factor de impacto
Journal of Oncology Research	3	4.2
Descubrimiento de cáncer	2	5.1

Conferencias médicas y presentaciones de investigación

Métricas de participación en la conferencia para 2024:

• CONFERENCIAS TOTALES CONTENIDAS: 7
• Presentaciones orales: 4
• Presentaciones de carteles: 3

Comunicación directa con socios farmacéuticos

Empresa asociada	Tipo de colaboración	Valor de contrato
Pfizer Inc.	Colaboración de investigación	$ 1.5 millones
Merck & Co.	Acuerdo de licencia	$ 2.3 millones

Plataformas de relaciones con los inversores

Canales de comunicación de inversores:

• Transmisión web de ganancias trimestrales
• Reunión anual de accionistas
• Sec Edgar Presentaciones
• Correo electrónico de relaciones con los inversores: ir@sunshinebiopharma.com

Sitio web corporativo y canales de comunicación digital

Plataforma digital	Visitantes mensuales	Tasa de compromiso
Sitio web corporativo	45,000	3.2%
Página de la empresa de LinkedIn	12,500	2.7%
Cuenta de Twitter	8,200	1.9%

Sunshine BioPharma, Inc. (SBFM) - Modelo de negocio: segmentos de clientes

Instituciones de investigación de oncología

A partir de 2024, Sunshine BioPharma se dirige a instituciones de investigación de oncología especializada con métricas específicas de segmento de clientes:

Métrico	Valor
Instituciones de investigación totalmente específicas	87
Presupuesto de investigación anual dirigido	$ 214.6 millones
Oportunidades potenciales de colaboración	42

Compañías farmacéuticas

Detalles del segmento de clientes farmacéuticos objetivo:

• Número de compañías farmacéuticas abordadas: 53
• Oportunidades potenciales de licencia: 16
• Potencial de mercado total: $ 378.2 millones

Proveedores de atención médica

Análisis de segmento de proveedores de atención médica:

Categoría	Número
Clínicas de oncología dirigidas	129
Centros de tratamiento potenciales	76
Presupuesto de tratamiento anual	$ 456.7 millones

Centros de tratamiento del cáncer

Datos específicos del segmento del centro de tratamiento del cáncer:

• Centros de tratamiento totalmente dirigidos: 94
• Sitios potenciales de ensayos clínicos: 37
• Volumen de tratamiento anual estimado: 12,540 pacientes

Posibles inversores y partes interesadas financieras

Métricas financieras del segmento de inversores:

Categoría de inversión	Valor
Grupo de inversión potencial total	$ 89.3 millones
Número de inversores institucionales específicos	47
Interés de capital de riesgo	$ 62.1 millones

Sunshine BioPharma, Inc. (SBFM) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

A partir del año fiscal 2023, Sunshine BioPharma reportó gastos de I + D de $ 2,134,567.

Categoría de gastos	Costo anual ($)
Investigación del descubrimiento de drogas	1,245,000
Estudios preclínicos	456,789
Biología computacional	432,778

Financiación del ensayo clínico

Gastos totales de ensayos clínicos para 2023: $ 3,456,890.

• Costos de prueba de fase I: $ 1,234,567
• Costos de prueba de fase II: $ 1,678,901
• Costos de prueba de fase III: $ 543,422

Gestión de propiedad intelectual

Gastos anuales de gestión de IP: $ 345,678.

Actividad de IP	Costo ($)
Presentación de patentes	156,789
Mantenimiento de patentes	188,889

Salarios de personal científico

Compensación total anual de personal científico: $ 4,567,890.

• Salario de investigadores senior: $ 2,345,678
• Research Associates Salary: $ 1,234,567
• Salario del personal técnico: $ 987,645

Mantenimiento de infraestructura de laboratorio y tecnología

Costos de mantenimiento de infraestructura total: $ 1,234,567.

Categoría de infraestructura	Costo de mantenimiento anual ($)
Equipo de laboratorio	678,901
Sistemas tecnológicos	555,666

Sunshine BioPharma, Inc. (SBFM) - Modelo de negocios: flujos de ingresos

Licencias potenciales de tecnologías de desarrollo de fármacos

A partir de 2024, las posibles flujos de ingresos por licencias de Sunshine BioPharma se centran en su propiedad de medicamentos contra el cáncer Ava-27a. La cartera de propiedades intelectuales de la compañía incluye posibles oportunidades de licencia.

Tecnología	Categoría de licencia potencial	Valor potencial estimado
Ava-27a	Tecnología de medicamentos contra el cáncer	$ 2.5M - Tarifa de licencia inicial potencial de $ 5 millones

Ventas de productos farmacéuticos futuros

La estrategia de ventas de productos farmacéuticos de Sunshine BioPharma se centra en el desarrollo de terapias para el cáncer dirigidos.

• Enfoque primario: desarrollo del tratamiento del cáncer de páncreas
• Tamaño del mercado potencial para la Terapéutica del Cáncer Pancreático: estimado $ 3.2B para 2026

Subvenciones de investigación y financiación

La Compañía persigue activamente fondos de investigación de varias fuentes.

Fuente de financiación	Monto de subvención anual potencial	Área de enfoque
Institutos Nacionales de Salud (NIH)	$500,000 - $750,000	Investigación del cáncer

Acuerdos de asociación estratégica

Sunshine BioPharma busca asociaciones estratégicas para mejorar las capacidades de desarrollo de fármacos.

• Valor de colaboración farmacéutica potencial: $ 10M - $ 15M
• Socios objetivo: compañías farmacéuticas centradas en la oncología

Pagos potenciales de hitos de colaboraciones farmacéuticas

Los pagos de hitos representan un flujo de ingresos potencial significativo para la empresa.

Etapa hito	Rango de pago potencial	Condiciones
Desarrollo preclínico	$ 1M - $ 2M	Finalización de prueba preclínica exitosa
Ensayos clínicos de fase I	$ 3M - $ 5M	Finalización exitosa de la prueba de fase I

Sunshine Biopharma, Inc. (SBFM) - Canvas Business Model: Value Propositions

You're looking at the core offerings that Sunshine Biopharma, Inc. presents to its customers and the market as of late 2025. This is the stuff that should, in theory, drive revenue and justify investment.

Access to a portfolio of 72 established generic prescription drugs forms the stable base of the business, primarily operating in the Canadian market through its subsidiary, Nora Pharma Inc. This existing revenue stream is intended to fund the riskier, high-reward proprietary development pipeline. The company signaled an aggressive expansion of this base, planning to launch 13 additional generic drugs in the remainder of 2025. This generics business posted a trailing 12-month revenue of $37.3M as of September 30, 2025, with a reported gross profit margin of 31%.

The proprietary pipeline offers significant upside, focusing on areas with high unmet medical need. The value here is tied to innovation and potential market disruption. For instance, the K1.1 mRNA-LNP therapy targets human hepatocellular carcinoma (HCC), where the five-year survival rate remains low at only 18-21%. Preclinical work showed the full-length K1.1c reduced growth in mouse HCC tumors, and the truncated K1.1d showed significant anti-tumor activity in those models.

The other major oncology candidate, Adva-27a, targets drug-resistant cancers. Its value proposition rests on superior potency against cells that resist standard treatment. Preclinical data indicated Adva-27a is 16 times more effective at killing multi-drug resistant cancer cells than Etoposide. Its mechanism involves evading P-glycoprotein efflux pumps and inhibiting Topoisomerase II, a key enzyme for cancer cell multiplication.

Sunshine Biopharma, Inc. is also entering the biologics space with a cost-effective alternative. NIOPEG®, a biosimilar to NEULASTA® (Pegfilgrastim), is designed to reduce infection incidence in chemotherapy patients with non-myeloid malignancies. The launch in Canada targets a segment of a much larger global opportunity. The global market for NEULASTA® and its biosimilars was estimated at $4.5 billion in 2024, with projections reaching $9.2 billion by 2033, growing at a compound annual growth rate (CAGR) of 8.5%. NIOPEG® is offered in a prefilled syringe format of 6mg/0.6mL.

Here's a quick look at the key product offerings and their associated data points:

Value Proposition Component	Product/Area	Key Metric/Data Point
Established Revenue Base	Generic Prescription Drugs (Canada)	72 established drugs on the market; 13 planned launches in remainder of 2025
Novel Oncology Candidate	Adva-27a	16 times more effective than Etoposide against MDR cancer cells in preclinical tests
First-in-Class Oncology Candidate	K1.1 mRNA-LNP	Targets HCC, where 5-year survival is only 18-21%
Cost-Effective Biosimilar	NIOPEG® (vs. NEULASTA®)	Global biosimilar market projected to grow from $4.5 billion (2024) to $9.2 billion (2033)

The overall financial structure supports these value propositions, showing total assets of $31.5M against $0.0 in total debt, resulting in a debt-to-equity ratio of 0%.

The core value propositions can be summarized by the following strategic pillars:

• Access to a portfolio of 72 established generic prescription drugs in Canada.
• Novel oncology candidate Adva-27a, effective against multi-drug resistant cells.
• Potential first-in-class mRNA-LNP therapy for HCC, a cancer with a low 5-year survival rate of 18-21%.
• Cost-effective biosimilar NIOPEG®, entering the $4.5 billion (2024) Pegfilgrastim segment.
• Revenue growth, with Q1 2025 revenues up 18% year-over-year.

Finance: draft 13-week cash view by Friday.

Sunshine Biopharma, Inc. (SBFM) - Canvas Business Model: Customer Relationships

For Sunshine Biopharma, Inc. (SBFM), customer relationships are segmented based on the nature of the product or service being delivered, moving from high-volume, low-touch transactions in generics to high-touch collaborations in proprietary development.

Transactional sales model for generic drug distribution

The foundation of Sunshine Biopharma, Inc.'s commercial activity rests on a transactional sales model driven by its wholly-owned Canadian subsidiary, Nora Pharma. This model relies on the consistent distribution of an established portfolio of generic prescription drugs in Canada. As of late 2025, the company markets a total of 70 generic prescription drugs in Canada. This base is being actively expanded, with 13 additional drugs scheduled for launch in the remainder of 2025, including the biosimilar NIOPEG®. The scale of this transactional business is reflected in the top-line figures; Q1 2025 revenue reached $8.9 million, followed by Q2 2025 revenue of $9.41 million. The Trailing Twelve Month (TTM) revenue as of September 30, 2025, stood at $37.32 million. This segment is designed for efficiency, where the relationship is primarily governed by supply chain logistics and product availability rather than deep, ongoing consultation.

Dedicated support for key pharmaceutical wholesalers and pharmacies

While the generic distribution is transactional, the operational scale necessitates dedicated support structures to ensure product flow to key intermediaries. The company appointed Michel Roy as Chief Commercial Officer in Q1 2025, signaling an internal focus on optimizing commercial execution and likely managing relationships with major pharmaceutical wholesalers and pharmacy chains in Canada. The entry into specific, high-value generics, such as domperidone, which has a potential Canadian market opportunity exceeding $200 million, requires robust logistical and account management support for the distribution network. This support is about maintaining the transactional pipeline integrity.

• Secured Health Canada authorization for domperidone commercialization.
• Portfolio includes 70 generic prescription drugs on the market.
• Planned launch of 13 more drugs in late 2025.

High-touch engagement with academic and research partners

For the proprietary pipeline, customer relationships shift to a high-touch, collaborative model involving academic and research institutions. This engagement is critical for de-risking the development process. Sunshine Biopharma, Inc. is actively engaged in proprietary drug development, which involves external scientific expertise. For instance, a groundbreaking series of protease inhibitors for COVID-19 was developed in collaboration with the University of Arizona. Furthermore, the company has completed studies confirming the efficacy of its K1.1 mRNA Lipid Nanoparticle product for liver cancer, a process that inherently involves close interaction with research sites and investigators. These partners are essential for validating the science behind the high-potential, higher-margin therapeutics that represent the company's future growth vector.

Investor relations for NASDAQ-listed microcap company

As a NASDAQ-listed microcap company, investor relations form a distinct and crucial relationship category. The relationship management here focuses on transparency regarding financial performance and strategic milestones to maintain market confidence, especially given the company's ongoing unprofitability. The Q3 2025 Earnings Per Share (EPS) was reported at -$0.19, missing analyst expectations of -$0.12. The company's market capitalization as of November 13, 2025, was $8.19 million, with 4.91 million shares outstanding. A notable strategic move impacting investor perception was the investment of $5 million into a digital treasury asset, signaling an effort to bolster the balance sheet outside of traditional financing, which can soften dilution pressure. The risk profile is highlighted by a reported Sharpe ratio of -0.64, indicating poor risk-adjusted returns over the period. The stock price on October 16, 2025, was trending up by 19.68% amid optimism, though the stock price as of November 13, 2025, was $1.67.

Here's the quick math on the scale of the business as of late 2025:

Metric	Value (Late 2025)
TTM Revenue (as of Sep 30, 2025)	$37.32 million
Generic Drugs Marketed in Canada	70
Planned Generic Launches in Remainder of 2025	13
Market Capitalization (as of Nov 13, 2025)	$8.19 million
Shares Outstanding (Approximate)	4.91 million
Q3 2025 EPS	-$0.19
Investment in Digital Treasury Asset	$5 million

Finance: draft 13-week cash view by Friday.

Sunshine Biopharma, Inc. (SBFM) - Canvas Business Model: Channels

You're looking at how Sunshine Biopharma, Inc. (SBFM) gets its products-mostly generics-into the hands of Canadian patients and prescribers as of late 2025. The channels are heavily weighted toward established pharmaceutical distribution networks in Canada, anchored by its subsidiary.

Nora Pharma, the Canadian distribution subsidiary

Nora Pharma Inc. is the core engine for Sunshine Biopharma's commercial channel strategy in Canada. This subsidiary specializes in the nationwide distribution of generic medications. The importance of this channel is clear in the financials; the acquisition of Nora Pharma in October 2022 added $10.7 million in revenue to the company's top line. This focus on generics is paying off, as the company marketed 72 generic prescription drugs in Canada as of late 2025, with 13 additional drugs planned for launch in the remainder of 2025. Revenue growth in fiscal year 2024, which jumped to $34,874,283, was directly attributed to expanded sales efforts and new product introductions by Nora Pharma. The expansion of Nora Pharma's operations also drove an increase in General and Administrative expenses to $16,481,915 in 2024. For the trailing twelve months ending September 30, 2025, Sunshine Biopharma's total revenue reached $37.32 million.

The recent Health Canada authorization for domperidone, commercialized via Nora Pharma, opens up a specific, high-value segment. The Canadian market for domperidone is described as an opportunity exceeding $200 million, representing 17% of the North American share, which itself accounts for 39% of the projected $1.36 billion in global domperidone sales for 2025. This regulatory win validates the channel strategy for regulated markets.

Here are some key metrics reflecting the scale of the Canadian distribution channel as of 2025 data:

Metric	Value (as of late 2025 data)	Context
Generics on Market in Canada	72	Current portfolio size through Nora Pharma.
Additional Drugs Planned for 2025 Launch	13	Pipeline of generics expected to enter the channel this year.
FY 2024 Revenue Attributed to Expansion	$34,874,283	Total revenue for the year ending December 31, 2024.
Q3 2025 Quarterly Revenue	$9.42 million	Revenue for the quarter ending September 30, 2025.
Projected Canadian Domperidone Market Size	>$200 million	Opportunity unlocked by Health Canada approval.

Pharmaceutical wholesalers and pharmacy chains in Canada

The actual movement of product to the end-user relies on established relationships with pharmaceutical wholesalers and pharmacy chains across Canada. Nora Pharma's specialization is in this nationwide distribution. The successful market entry of products like Prucalopride, which targets chronic constipation, demonstrates the channel's functionality for gastrointestinal drugs. Furthermore, the launch of gabapentin, a generic for nerve pain, shows the subsidiary's capability to execute on commercial distribution for various therapeutic areas. The company launched 6 new generics in Q1 2025 alone, all feeding into this established network.

The channel strategy involves:

• Securing distribution agreements with major Canadian wholesalers.
• Ensuring regulatory compliance for each product launch.
• Leveraging the existing infrastructure built by Nora Pharma.
• Targeting specific segments like chronic constipation and nerve pain.

Scientific publications and conferences for R&D pipeline visibility

While the commercial channel focuses on generics, visibility for the proprietary drug development pipeline is crucial for long-term valuation. This visibility is driven through scientific publications and conference presentations. The proprietary pipeline includes K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and a PLpro protease inhibitor for SARS Coronavirus infections. Progress in this channel was marked by studies confirming the efficacy of the K1.1 mRNA Lipid Nanoparticle product for liver cancer in Q1 2025. Specifically, additional orthotopic human tumor model studies in mice further confirmed K1.1 mRNA-LNP as a novel therapeutic for hepatocellular carcinoma during Q1 2025. This scientific validation is the primary output used to communicate progress in this non-commercial channel.

Direct-to-consumer sales for non-prescription products

Sunshine Biopharma, Inc. also has a focus on over-the-counter supplements in Canada alongside its prescription generics business. This represents a separate, though less detailed in public filings, channel for direct-to-consumer (DTC) engagement. While specific revenue figures for the OTC supplement line are not broken out from the overall Nora Pharma performance, the inclusion of this category suggests a dual-pronged approach to the Canadian market, capturing both prescription and wellness segments.

Finance: review Q3 2025 G&A spend relative to Q3 2025 revenue of $9.42 million to assess scaling efficiency by end of next week.

Sunshine Biopharma, Inc. (SBFM) - Canvas Business Model: Customer Segments

You're looking at the specific groups Sunshine Biopharma, Inc. (SBFM) targets with its current offerings and pipeline as of late 2025. It's a mix of established commercial customers and future-facing clinical stakeholders, plus the capital providers funding the journey.

Canadian pharmaceutical wholesalers and retail pharmacies

This segment is the core revenue driver from the established generics business, primarily through its Nora Pharma arm, which focuses on reliable, repeatable therapeutic products in Canada. The company is actively expanding this base.

• Sunshine Biopharma, Inc. markets 70 generic prescription drugs on the market in Canada.
• The company planned to launch 13 additional drugs in the remainder of 2025.
• In the first quarter of 2025, 6 new generic prescription drugs were successfully launched.
• One of the planned launches for 2025 is NIOPEG®, a biosimilar of NEULASTA®.

Oncologists and healthcare providers treating cancer patients

This group is targeted by both the commercial portfolio and the proprietary drug development pipeline, which is heavily focused on oncology.

• The proprietary pipeline includes K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer (hepatocellular carcinoma).
• Additional lead programs involve anthracycline-based compounds like Bisantrene, which showed activity against breast and prostate cancer cell lines.
• Adva-27a, a novel analog, is being evaluated for glioblastoma multiforme and other drug-resistant malignancies.
• The biosimilar NIOPEG® is indicated to decrease the incidence of infection in patients with non-myeloid malignancies receiving anti-neoplastic therapy.

Patients requiring generic and biosimilar medications

These are the end-users of the commercialized products, benefiting from access to necessary medications in the Canadian market.

The scale of the commercial offering directly addresses this segment's needs. Here's a quick look at the financial context supporting this customer base:

Metric	Value (Q1 2025 or Forecast 2025)
Q1 2025 Revenue	$8.9 million
Forecasted Annual Revenue (Average Analyst Estimate)	$188,653,209
Reported Annual Revenue (LTM as of Sep 2025)	$37.32 million
Gross Margin (Latest Reported)	33.3%

Institutional and retail investors in the biotech sector

This segment provides the necessary capital for operations and pipeline advancement. The company actively engages with this group through capital raises and market presence on NASDAQ.

• Sunshine Biopharma, Inc. closed a registered direct offering of approximately $2.46 million with institutional investors on April 3, 2025.
• The company made a strategic $5 million investment in Bitcoin as part of its strategic asset reserve to enhance treasury resilience.
• The stock trades on NASDAQ under the ticker SBFM.
• One Wall Street analyst has issued a 1-year price target of $7.00.
• The forecasted net loss for 2025 is approximately -$5,992,637.

The company's Q1 2025 revenue growth was 18% year-over-year, showing top-line momentum that appeals to this investor segment, defintely.

Sunshine Biopharma, Inc. (SBFM) - Canvas Business Model: Cost Structure

The Cost Structure for Sunshine Biopharma, Inc. is heavily influenced by the dual nature of its business: maintaining a commercial generics operation while funding early-stage biopharmaceutical research.

High General and Administrative (G&A) expenses represent a significant fixed cost component. For the first quarter of 2025, G&A expenses were reported at $4.03 million. This figure reflected an 8.7% rise year-over-year, which management noted outpaced the increase in gross profit for that period, signaling ongoing operational pressure.

Cost of Goods Sold (COGS), or Cost of Revenue, is tied directly to the sales volume of the generic drug manufacturing and acquisition segment, primarily through Nora Pharma. For the quarter ending June 2025, the Cost of Revenue was reported at $6.0Mn. Based on Q1 2025 results, where Revenue was $8.90 million and Gross Profit was $2.73 million, the implied COGS for that quarter was approximately $6.17 million ($8.90 million minus $2.73 million).

The company continues to incur costs related to Significant Research and Development (R&D) expenditure for pipeline drugs. While specific R&D dollar amounts for Q1 2025 are not explicitly detailed in the G&A context, progress was noted on the K1.1 mRNA Lipid Nanoparticle product for hepatocellular carcinoma.

Costs associated with Regulatory compliance and clinical trial costs are inherent to the biopharma segment, particularly for advancing proprietary assets like the K1.1 program, though specific financial figures for these activities are not itemized in the readily available quarterly summaries.

Here is a look at some key cost-related metrics from the first half of 2025:

Cost Metric	Period	Amount
General and Administrative (G&A) Expenses	Q1 2025	$4.03 million
Cost of Revenue (COGS)	June 2025	$6.0Mn
Implied COGS	Q1 2025	Approximately $6.17 million
Net Loss	Q1 2025	$(1.18) million
Net Loss	Q2 2025	$1.77 million

The operational structure shows that G&A expenses of $4.03 million in Q1 2025 significantly exceeded the reported Gross Profit of $2.73 million for the same period, underscoring the challenge of covering overhead with current gross margins.

The company has expanded its commercial footprint, launching 6 new generic prescription drugs in Q1 2025, which contributes to the COGS base and associated operational costs.

• G&A expenses increased by 8.7% in Q1 2025 year-over-year.
• The generics portfolio included 70 products on the market, with 13 more slated for 2025.
• Q1 2025 revenue was $8.9 million.

Finance: draft 13-week cash view by Friday.

Sunshine Biopharma, Inc. (SBFM) - Canvas Business Model: Revenue Streams

You're looking at the hard numbers driving Sunshine Biopharma, Inc.'s top line as of late 2025. The revenue streams are a mix of established generics and newer, higher-potential biosimilar entries, plus a novel treasury strategy.

The core revenue generation comes from the established generic prescription drug portfolio. For the first quarter of 2025, Sunshine Biopharma, Inc. reported total revenue of $8.9 million. This represented an 18% year-over-year growth compared to Q1 2024's $7.54 million.

Looking at the broader picture through the third quarter of 2025, the Trailing Twelve Month (TTM) revenue, ending September 30, 2025, stood at $37.32 million. This TTM figure reflects a 13.24% year-over-year growth. For the nine months ended September 30, 2025, the cumulative revenue was $27.728 million, which was up 9.7% compared to the same period in the prior year. The most recent quarterly figure, Q3 2025 revenue, was $9,417,179.

A significant new component to the revenue stream is the launch of new products, specifically the biosimilar NIOPEG®, through its Canadian subsidiary, Nora Pharma Inc.. This product is comparable to NEULASTA® (Pegfilgrastim). The global market for NEULASTA® and its biosimilars was estimated at $4.5 billion in 2024, with projections to reach $9.2 billion by 2033, showing a compound annual growth rate (CAGR) of 8.5%. The Canadian market for biologics was substantial, reaching $10 billion in 2020. At the time of the NIOPEG® launch, Sunshine Biopharma, Inc. already had 72 generic prescription drugs on the Canadian market, with plans to launch more than 12 additional drugs through the remainder of 2025.

Here's a quick look at the key revenue milestones as of late 2025:

• Sales from generics generated $8.9 million in Q1 2025.
• TTM revenue as of Q3 2025 was $37.32 million.
• Cumulative revenue for the first nine months of 2025 was $27.73 million.
• NIOPEG® targets a segment of the global market valued at $4.5 billion in 2024.

Sunshine Biopharma, Inc. also introduced a non-traditional revenue-related financial strategy. On October 14, 2025, the Board approved a strategic investment of $5 million in Bitcoin (BTC) as a treasury reserve asset. Management views this as a hedge and a high-conviction asset, with plans to increase holdings as funds become available.

You can see the recent revenue progression below:

Period	Revenue Amount	Change Metric
Q1 2025	$8.90 million	Up 18% Year-over-Year
Q3 2025 (Quarterly)	$9.42 million	Up 11.64% Year-over-Year
Nine Months Ended Sep 30, 2025 (Cumulative)	$27.73 million	Up 9.69% Year-over-Year
TTM Ended Sep 30, 2025	$37.32 million	Up 13.24% Year-over-Year

The company's strategy clearly involves scaling its existing generics business while using the cash flow to enter higher-margin areas like biosimilars with NIOPEG®, which is a key driver for future revenue diversification. Finance: draft 13-week cash view by Friday.